May 13, 2008 – Applied NeuroSolutions, Inc. (OTC BB:APNS), a company focused on the development of products for the early diagnosis and treatment of Alzheimer’s disease (“AD”), announced an initiative to provide its P-Tau 231 cerebrospinal fluid (CSF) test to companies undertaking AD clinical trials. Potential customers, which include pharmaceutical, biotechnology and imaging companies, may use the P-Tau 231 test to aid in screening patients for clinical trials and to track P-Tau 231 levels pre- and post-drug treatment. Applied NeuroSolutions has identified over 50 companies with 100 plus compounds in active clinical development for AD. Revenue generated from providing this service would help support the further development of Applied NeuroSolutions’s diagnostic pipeline, with a goal of delivering a serum-based test for the early diagnosis of AD... Applied NeuroSolutions' Press release -
Friday, May 23, 2008
Applied NeuroSolutions : P-Tau 231 Test for Use in Alzheimer's Disease Clinical Trials
May 13, 2008 – Applied NeuroSolutions, Inc. (OTC BB:APNS), a company focused on the development of products for the early diagnosis and treatment of Alzheimer’s disease (“AD”), announced an initiative to provide its P-Tau 231 cerebrospinal fluid (CSF) test to companies undertaking AD clinical trials. Potential customers, which include pharmaceutical, biotechnology and imaging companies, may use the P-Tau 231 test to aid in screening patients for clinical trials and to track P-Tau 231 levels pre- and post-drug treatment. Applied NeuroSolutions has identified over 50 companies with 100 plus compounds in active clinical development for AD. Revenue generated from providing this service would help support the further development of Applied NeuroSolutions’s diagnostic pipeline, with a goal of delivering a serum-based test for the early diagnosis of AD... Applied NeuroSolutions' Press release -
